Source-grounded facts extracted from Vir Biotechnology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Timothy Coughlin was appointed as Director and Chair of the Audit Committee at Vir Biotechnology, Inc..
“the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders, as well as the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board, in each case effective immediately.”
Vir Biotechnology, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-26 meeting.
“Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 137,048,756 153,836 1,164,682 0”
Vir Biotechnology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-26 meeting.
“Proposal 2. Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 108,453,963 11,863,405 1,372,563 16,677,343”
Vir Biotechnology, Inc. shareholders approved Election of Directors at the 2026-05-26 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Robert More, MBA 114,856,835 6,833,096 16,677,343 Janet Napolitano, J.D. 67,235,175 54,454,756 16,677,343 Elliott Sigal, M.D., Ph.D. 115,030,681 6,659,250 16,677,343”
Saira Ramasastry departed as Director at Vir Biotechnology, Inc..
“On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.”
Vir Biotechnology, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $125.7 million, or $0.85 per share, basic and diluted, EPS $0.85 per share, basic and diluted.
“On May 6, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Vir Biotechnology, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $141.1 million (effective 2026-02-25).
“On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).”
Vir Biotechnology, Inc. issued 7,239,382 shares of common stock to Astellas for an aggregate purchase price of approximately $75 million.
“Astellas has agreed to purchase 7,239,382 shares of Vir Bio’s common stock, par value $0.0001 per share (Common Stock), for an aggregate purchase price of approximately $75 million”
Vir Biotechnology, Inc. entered into Stock Purchase Agreement with Astellas US LLC valued at approximately $75 million (effective 2026-02-19).
“Concurrently with the execution of the Agreement, Vir Bio also entered into the SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of Vir Bio’s common stock, par value $0.0001 per share (Common Stock), for an aggregate purchase price of approximately $75 million, subject to customary closing conditions.”
Vir Biotechnology, Inc. entered into Collaboration and License Agreement with Astellas US LLC valued at $335 million in upfront and near-term milestone payments (effective 2026-02-19).
“On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).”
Vir Biotechnology, Inc. entered into License Agreement with Norgine Pharma UK Limited valued at EUR 55 million (effective 2025-12-16).
“On December 16, 2025, Vir Biotechnology, Inc. (Vir Bio) and Norgine Pharma UK Limited (together with its affiliates in the Norgine group of companies, Norgine) entered into a License Agreement (the Agreement) with respect to certain commercial rights to the combination of tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta (CHD).”
Maninder Hora was appointed as Executive Vice President and Chief Technical Operations Officer at Vir Biotechnology, Inc..
“The Company has appointed Maninder Hora, Ph.D. to the role of Executive Vice President and Chief Technical Operations Officer, effective February 27, 2025, and Dr. Hora will assume Dr. Hanly’s responsibilities.”
Ann (Aine) M. Hanly departed as Executive Vice President and Chief Technology Officer at Vir Biotechnology, Inc..
“On January 24, 2025, Vir Biotechnology, Inc. (the “Company”) announced that Ann (Aine) M. Hanly, Ph.D., the Company’s Executive Vice President and Chief Technology Officer, will be leaving the Company on February 26, 2025.”
Vir Biotechnology, Inc. completed an acquisition involving Sanofi for $100 million plus $75 million in an escrowed milestone payment (closed 2024-09-09).
“masking platform for oncology and infectious disease, acquired by Sanofi from Amunix. At Closing, the Company made an upfront payment to Sanofi in the amount of $100 million plus $75 million in an escrowed milestone payment that is subject to SAR446368 (AMX-525) achieving “first in human dosing” by 2026. Sanofi will also be eligible to receive up to”
Jason O'Byrne was appointed as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..
“the Company announced that Jason O’Byrne, MBA, has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 2, 2024”
Vir Biotechnology, Inc. announced a restructuring with charges of $11 million to $13 million affecting the Company's overall operations, including phasing out programs in influenza, COVID-19, and T cell-based viral vector platform (approximately 25% of the Company’s workforce, or approximately 140 employees).
“believes is appropriate to support its streamlined portfolio and strategic priorities. As a result of these changes, the Company expects to incur restructuring charges between $11 million to $13 million, primarily related to employee severance cash expenditures. The Company anticipates recognizing these expenses through the fourth quarter of 2024, resulting in”
Vir Biotechnology, Inc. reported first quarter ended March 31, 2024 results: revenue $56.4 million.
“cash equivalents and investments declined by approximately $118 million during the first quarter of 2024. Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023. Revenues were comprised of the following components: Three Months Ended March 31, 2024 2023 % Change (in millions)”
Sung Lee resigned as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..
“On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the “Company”), informed the Company that he will be stepping down from his role, effective May 3, 2024, to pursue another career opportunity.”
Vir Biotechnology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 22, 2024, the Company issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2023.”
Vir Biotechnology, Inc. terminated Letter Agreement with Glaxo Wellcome UK Limited (effective 2024-02-21).
“On February 21, 2024, the Parties entered into a letter agreement (the “Letter Agreement”) pursuant to which the Parties mutually agreed to terminate their collaboration on the Influenza Program under the DCA.”
Phil Pang departed as Executive Vice President and Chief Medical Officer at Vir Biotechnology, Inc..
“On February 20, 2024, Vir Biotechnology, Inc. (the “Company”) announced that Executive Vice President and Chief Medical Officer, Phil Pang, M.D., Ph.D. has decided to leave the Company at the end of March 2024 to spend more time with his family.”
Vir Biotechnology, Inc. announced a restructuring with charges of $30 million to $40 million affecting research and development facilities (approximately 12% of the workforce or 75 positions).
“continue at the Company’s sites in San Francisco, California and Bellinzona, Switzerland. As a result of these changes, the Company estimates that it will incur charges between $30 million to $40 million, primarily related to facility closures and to a lesser extent, employee severance costs. Of the total charges, the Company estimates that $3 million to $4 million”
Vir Biotechnology, Inc. terminated Prior Sales Agreement with TD Cowen (effective 2023-11-03).
“On November 3, 2023, and in connection with entering into the Sales Agreement, the Company and TD Cowen agreed to terminate, effective as of immediately prior to the entry by the parties into the Sales Agreement, the sales agreement that the Company previously entered into with TD Cowen on November 10, 2020 (the “Prior Sales Agreement”).”
Vir Biotechnology, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-03).
“On November 3, 2023, Vir Biotechnology, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, as sales agent (“TD Cowen”), pursuant to which the Company may from time to time offer and sell shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $300.0 million, through or to TD Cowen, acting as sales agent or principal.”
Vir Biotechnology, Inc. reported third quarter ended September 30, 2023 results: revenue $2.6 million.
“Total revenues for the quarter ended September 30, 2023, were $2.6 million compared to $374.6 million for the same period in 2022.”
Vir Biotechnology, Inc. amended BARDA Agreement with Biomedical Advanced Research and Development Authority (BARDA) valued at $50 million (effective 2023-09-29).
“On September 29, 2023, Vir Biotechnology, Inc. (the “Company” or “Vir”) and the Biomedical Advanced Research and Development Authority (“BARDA”), part of the U.S. Department of Health and Human Services’ (“HHS”) Administration for Strategic Preparedness and Response, entered into Amendment No. P00001 to their Other Transaction Authority Agreement (as amended, the “BARDA Agreement”) pursuant to which BARDA awarded the Company $50 million in new funding”
Johanna Friedl-Naderer departed as Executive Vice President and Chief Operating Officer at Vir Biotechnology, Inc..
“On September 20, 2023, Vir Biotechnology, Inc. (the “Company”) announced that Johanna Friedl-Naderer, the Company’s Executive Vice President and Chief Operating Officer, will be leaving the Company on September 29, 2023.”
Vir Biotechnology, Inc. reported preliminary financial results for the quarter ended June 30, 2023.
“Although it has not finalized its full financial results for the quarter ended June 30, 2023, Vir Biotechnology, Inc. (the “Company”) disclosed in a press release on July 20, 2023, that it had cash, cash equivalents and investments of approximately $1.9 billion as of June 30, 2023.”
Vir Biotechnology, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-19 meeting.
“Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment by the Audit Committee”
Vir Biotechnology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-05-19 meeting.
“Proposal 2. Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.”
Vir Biotechnology, Inc. shareholders approved Election of four Class I Directors at the 2023-05-19 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the four persons listed below as Class I Directors”
Vir Biotechnology, Inc. reported first quarter ended March 31, 2023 results: revenue $63.0 million.
“Total revenues for the quarter ended March 31, 2023, were $63.0 million compared to $1.2 billion for the same period in 2022.”
Vir Biotechnology, Inc.: Amended and restated bylaws to reflect recent legal changes, procedural updates, and enhance stockholder proposal and director nomination requirements (effective 2023-03-02).
“On March 2, 2023, the Board of Directors of Vir Biotechnology, Inc. (the “Company”) unanimously adopted amended and restated bylaws of the Company (as so amended and restated, the “Bylaws”). The Bylaws, which became effective upon adoption, make modifications to reflect recent changes to applicable laws as well as certain procedural and other updates.”
Vir Biotechnology, Inc. reported the full year ended December 31, 2022 results: revenue $1.5 billion.
“– $1.5 billion of sotrovimab collaboration revenue recognized in 2022 –”
Vir Biotechnology, Inc. reported financial results for the fourth quarter ended December 31, 2022.
“Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.”
Sung Lee was appointed as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..
“On February 13, 2023, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Sung Lee as Executive Vice President and Chief Financial Officer of the Company, effective as of March 27, 2023 (the “Effective Date”).”
Howard Horn changed role as Chief Financial Officer at Vir Biotechnology, Inc..
“Howard Horn will step down as Chief Financial Officer of the Company effective upon Mr. Lee’s appointment on the Effective Date, and will remain with Vir as Executive Vice President until April 28, 2023, to assist with the transition.”
Vir Biotechnology, Inc. entered into Amendment No. 2 and Amendment No. 3 to the DCA with GSK (effective 2023-02-08).
“On February 8, 2023, the Company, and GSK entered into Amendment No. 2 and Amendment No. 3 to the DCA (collectively, the “DCA Amendments”).”
Marianne De Backer was appointed as Class II director at Vir Biotechnology, Inc..
“In addition, effective as of the Effective Date, the size of the Board will increase to 11 directors and Dr. De Backer will be appointed to fill the newly created vacancy to serve on the Board as a Class II director until the Company’s 2024 annual meeting of stockholders, and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.”
Marianne De Backer was appointed as Chief Executive Officer at Vir Biotechnology, Inc..
“On January 19, 2023, the Board appointed Marianne De Backer, MSc, Ph.D., MBA, as Chief Executive Officer of the Company, effective as of April 3, 2023 (the “Effective Date”).”
George Scangos retired as Chief Executive Officer and President at Vir Biotechnology, Inc..
“On January 19, 2023, George Scangos, Ph.D., notified the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) of his decision to retire as Chief Executive Officer and President effective as of the Effective Date (as defined below).”
Vir Biotechnology, Inc. reported financial results for third quarter ended September 30, 2022.
“On November 3, 2022, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Herbert (Skip) Virgin resigned as Executive Vice President, Research and Chief Scientific Officer at Vir Biotechnology, Inc..
“On July 11, 2022, Herbert (Skip) Virgin, M.D., Ph.D., notified Vir Biotechnology, Inc. (the “Company”) that he will step down as Executive Vice President, Research and Chief Scientific Officer of the Company effective August 31, 2022.”
Johanna Friedl-Naderer was appointed as Executive Vice President and Chief Operating Officer at Vir Biotechnology, Inc..
“Effective as of April 4, 2022, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Johanna Friedl-Naderer, age 54, to serve as Executive Vice President and Chief Operating Officer of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.